Elsevier

Schizophrenia Research

Volume 194, April 2018, Pages 86-90
Schizophrenia Research

Genetic correlation between smoking behaviors and schizophrenia

https://doi.org/10.1016/j.schres.2017.02.022Get rights and content

Abstract

Nicotine dependence is highly comorbid with schizophrenia, and the etiology of the comorbidity is unknown. To determine whether there is a genetic correlation of smoking behavior with schizophrenia, genome-wide association study (GWAS) meta-analysis results from five smoking phenotypes (ever/never smoker (N = 74,035), age of onset of smoking (N = 28,647), cigarettes smoked per day (CPD, N = 38,860), nicotine dependence (N = 10,666), and current/former smoker (N = 40,562)) were compared to GWAS meta-analysis results from schizophrenia (N = 79,845) using linkage disequilibrium (LD) score regression. First, the SNP heritability (h2g) of each of the smoking phenotypes was computed using LD score regression (ever/never smoker h2g = 0.08, age of onset of smoking h2g = 0.06, CPD h2g = 0.06, nicotine dependence h2g = 0.15, current/former smoker h2g = 0.07, p < 0.001 for all phenotypes). The SNP heritability for nicotine dependence was statistically higher than the SNP heritability for the other smoking phenotypes (p < 0.0005 for all two-way comparisons). Next, a statistically significant (p < 0.05) genetic correlation was observed between schizophrenia and three of the five smoking phenotypes (nicotine dependence rg = 0.14, CPD rg = 0.12, and ever/never smoking rg = 0.10). These results suggest that there is a component of common genetic variation that is shared between smoking behaviors and schizophrenia.

Introduction

Severe mental illness and nicotine dependence frequently co-occur. Individuals suffering from schizophrenia have much higher rates of smoking than the general population (Hartz et al., 2014) and smokers are more likely to suffer from schizophrenia (Gage et al., 2014, Gurillo et al., 2015, Myles et al., 2012, Sorensen et al., 2011, Zammit et al., 2003). Furthermore, much of the morbidity and premature mortality in individuals with schizophrenia can be attributed to smoking-related diseases (Brady et al., 1993, Colton and Manderscheid, 2006, Crump et al., 2013, Drake and Wallach, 1989, Olfson et al., 2015, Parks et al., 2006).

Given the severe public health consequences of the comorbidity of schizophrenia with nicotine dependence, understanding the etiology of this comorbidity is clinically important. Currently, schizophrenia is diagnosed and treated independently of nicotine dependence. Prognostically, there is already evidence that schizophrenia with comorbid nicotine dependence is more severe and has worse outcomes than schizophrenia without comorbid nicotine dependence (Gage et al., 2014, Sorensen et al., 2011, Tsoi et al., 2013, Zammit et al., 2003).

There are three non-exclusive models to explain the comorbidity between nicotine dependence and schizophrenia (Gage and Munafo, 2015a): (1) smoking may lead to the onset of schizophrenia; (2) schizophrenia may cause the development of nicotine dependence (self-medication, for example); and (3) there may be common underlying risk factors, environmental and genetic, that predispose to both schizophrenia and nicotine dependence. Recently, there has been growing evidence to suggest a causal pathway from smoking to schizophrenia. Studies have found that smoking prospectively predicts risk for schizophrenia (Gage et al., 2014, Kendler et al., 2015). Further, the observed association did not arise from smoking onset during the prodromal period of schizophrenia and demonstrated a clear dose-response relationship (Kendler et al., 2015).

There is new evidence that nicotine dependence and schizophrenia share contributory genetic factors. Recently, the Psychiatric Genetics Consortium identified 128 independent loci that contribute to the risk of developing schizophrenia (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). Interestingly, one locus recently identified as contributing to schizophrenia is the chromosome 15q24 locus, which contains the α5-α3-β4 nicotinic receptor subunit genes and is the strongest genetic contributor to nicotine dependence (Hancock et al., 2015, TAG, 2010). Although this is promising evidence of shared genetic factors between nicotine dependence and schizophrenia, because the analysis did not adjust for smoking, the finding may be due to confounding from smoking. A different study found positive associations both between nicotine dependence and polygenic risk scores for schizophrenia, and between schizophrenia and polygenic risk scores for cotinine levels (Chen et al., 2016). These complimentary analyses support the hypothesis that nicotine dependence and schizophrenia have shared genetic factors. However, additional studies are needed to clarify this relationship.

One approach to determining whether shared genetic factors contribute to multiple phenotypes is to estimate the genetic correlation between the phenotypes using linkage disequilibrium (LD) score regression (Bulik-Sullivan et al., 2015a, Bulik-Sullivan et al., 2015b). Using known LD between single nucleotide polymorphisms (SNPs), the intercept computed from LD score regression can be included in GWAS analyses as a powerful correction factor for the inflation of test statistics (Bulik-Sullivan et al., 2015b). In addition, the formula for LD score regression can be permuted to compute the genetic correlation between phenotypes based on GWAS results, termed genetic correlation (Bulik-Sullivan et al., 2015a).

LD score regression has been used to show genetic correlation between multiple psychiatric phenotypes (Bulik-Sullivan et al., 2015a), which included observed positive genetic correlation between schizophrenia and both the age of onset of smoking and cigarettes smoked per day (p < 0.05). However, to our knowledge, the genetic correlation between the full complement of smoking behaviors (including nicotine dependence) and schizophrenia has not been fully characterized. In this study, we use LD score regression to evaluate the genetic correlation between multiple smoking phenotypes and schizophrenia.

Section snippets

Smoking phenotypes

To evaluate the genetic correlation between smoking phenotypes and schizophrenia, five different smoking phenotypes were used (Table 1). Ever/never smoker was coded as a dichotomous phenotype, with ever smokers typically defined as having smoked 100 cigarettes lifetime (Tobacco and Genetics Consortium, 2010). Age of onset of smoking was a continuous phenotype that was log transformed for analysis, and was defined as the age of onset of regular smoking (Tobacco and Genetics Consortium, 2010).

Results

The first step was to estimate the heritability of the smoking phenotypes. The univariate SNP heritability, the proportion of phenotypic variance explained by GWAS SNPs, was evaluated for each smoking phenotype (Table 2). All the smoking phenotypes have statistically significant SNP heritability (p < 0.001). The phenotype with the highest magnitude of estimated SNP heritability (15%) was nicotine dependence. This is approximately double the estimated SNP heritability for the other smoking

Discussion

The results of this study show that (1) common genetic variation explains more phenotypic variance for nicotine dependence relative to other smoking phenotypes (i.e. higher SNP heritability), and (2) there is a component of common genetic variation that is shared between smoking behaviors and schizophrenia (i.e. nonzero genetic correlation).

LD score regression has identified multiple diseases that have shared genetic factors with schizophrenia (Bulik-Sullivan et al., 2015a). Of these, bipolar

Conflict of interest

All authors declare that they have no conflicts of interest.

Contributors

Drs. Hartz and Bierut designed the study and wrote the protocol. Drs. Hartz, Horton and Bierut designed and conducted statistical analyses. All authors contributed to data harmonization and interpretation of results. Dr. Hartz wrote the first draft of the manuscript. All authors contributed to and have approved the final manuscript.

Role of funding source

This study was funded by the NIH. The funding source had no role in the study design and analysis.

Acknowledgements

We thank the many participants of these studies. This work was supported by the National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) grant numbers K08 032680, R01 DA035825, R01 DA036583, R01 HL089897, R01 HL089856, K01 HL125858, R01-DE014899 and U01-DE018903. Funding support for the nicotine dependence study samples were previously described (Hancock et al., 2015). The content is solely the responsibility of the authors and does not necessarily represent the views of the

References (38)

  • J. Chen et al.

    Genetic relationship between schizophrenia and nicotine dependence

    Sci. Rep.

    (2016)
  • C.W. Colton et al.

    Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states

    Prev. Chronic Dis.

    (2006)
  • C. Crump et al.

    Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study

    Am. J. Psychiatry

    (2013)
  • R.E. Drake et al.

    Substance abuse among the chronic mentally ill

    Hosp. Community Psychiatry

    (1989)
  • S.H. Gage et al.

    Associations of cannabis and cigarette use with psychotic experiences at age 18: findings from the Avon Longitudinal Study of Parents and Children

    Psychol. Med.

    (2014)
  • D.B. Hancock et al.

    Genome-wide meta-analysis reveals common splice site acceptor variant in CHRNA4 associated with nicotine dependence

    Transl. Psychiatry

    (2015)
  • S.M. Hartz et al.

    Comorbidity of severe psychotic disorders with measures of substance use

    JAMA Psychiat.

    (2014)
  • T.F. Heatherton et al.

    The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire

    Br. J. Addict.

    (1991)
  • K.S. Kendler et al.

    Smoking and schizophrenia in population cohorts of Swedish women and men: a prospective co-relative control study

    Am. J. Psychiatry

    (2015)
  • Cited by (0)

    View full text